Hepatic stellate cells and microRNAs in pathogenesis of liver fibrosis

Journal of Clinical Medicine

Volumn 5, Issue 3, 2016, Pages

  Kitano, Mio ^a   Mark Bloomston, P ^b  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^b 21ST CENTURY ONCOLOGY   (United States)

Author keywords

Hepatic stellate cell; Liver disease; Liver fibrosis; MicroRNA

Indexed keywords

ARGONAUTE PROTEIN; CARBON TETRACHLORIDE; COLLAGEN; EXPORTIN 5; GLIAL FIBRILLARY ACIDIC PROTEIN; GLYCOPROTEIN; HEPATOCYTE NUCLEAR FACTOR 4ALPHA; INTERLEUKIN 6; INTERLEUKIN 8; MICRORNA; MICRORNA 143; MICRORNA 29; MITOGEN ACTIVATED PROTEIN KINASE 3; MONOCYTE CHEMOTACTIC PROTEIN 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLATELET DERIVED GROWTH FACTOR B; PLATELET DERIVED GROWTH FACTOR BB; PROTEIN KINASE B; PROTEOGLYCAN; REACTIVE OXYGEN METABOLITE; RNA INDUCED SILENCING COMPLEX; RNA POLYMERASE; SCATTER FACTOR; SOMATOMEDIN C; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG;

APOPTOSIS; BIOGENESIS; BIOINFORMATICS; CELL ACTIVATION; CELL MIGRATION; CELL PROLIFERATION; DISEASE COURSE; EPITHELIAL MESENCHYMAL TRANSITION; FIBROGENESIS; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE REPRESSION; KUPFFER CELL; LIVER CELL CARCINOMA; LIVER FIBROSIS; LIVER INJURY; MICROARRAY ANALYSIS; NONALCOHOLIC FATTY LIVER; PATHOGENESIS; PORTAL HYPERTENSION; REVIEW; RNA DEGRADATION; RNA TRANSLATION; STELLATE CELL;

EID: 85114271153     PISSN: None     EISSN: 20770383     Source Type: Journal    
DOI: 10.3390/jcm5030038     Document Type: Review

References (129)

1. Friedman, S.L. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J. Biol. Chem. 2000, 275, 2247-2250. [CrossRef] [PubMed]
2. Bataller, R.; Brenner, D.A. Hepatic stellate cells as a target for the treatment of liver fibrosis. Semin. Liver Dis. 2001, 21, 437-451. [CrossRef] [PubMed]
3. Bataller, R.; Brenner, D.A. Liver fibrosis. J. Clin. Investig. 2005, 115, 209-218. [CrossRef] [PubMed]
4. Friedman, S.L. Hepatic stellate cells: Protean, multifunctional, and enigmatic cells of the liver. Physiol. Rev. 2008, 88, 125-172. [CrossRef] [PubMed]
5. Lee, R.C.; Feinbaum, R.L.; Ambros, V. The C. Elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993, 75, 843-854. [CrossRef]
6. Engels, B.M.; Hutvagner, G. Principles and effects of microRNA-mediated post-transcriptional gene regulation. Oncogene 2006, 25, 6163-6169. [CrossRef] [PubMed]
7. Zimmerman, A.L.; Wu, S. MicroRNAs, cancer and cancer stem cells. Cancer Lett. 2011, 300, 10-19. [CrossRef] [PubMed]
8. Lewis, B.P.; Burge, C.B.; Bartel, D.P. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005, 120, 15-20. [CrossRef] [PubMed]
9. Krek, A.; Grun, D.; Poy, M.N.; Wolf, R.; Rosenberg, L.; Epstein, E.J.; MacMenamin, P.; da Piedade, I.; Gunsalus, K.C.; Stoffel, M. et al. Combinatorial microRNA target predictions. Nat. Genet. 2005, 37, 495-500.[CrossRef] [PubMed]
10. Homo Sapiens miRNAs. Available online: http://www.mirbase.org/cgi-bin/mirna_summary.pl?org=hsa (accessed on 17 March 2015).
11. Jovanovic, M.; Hengartner, M.O. MiRNAs and apoptosis: RNAs to die for. Oncogene 2006, 25, 6176-6187. [CrossRef] [PubMed]
12. Chen, C.Z.; Li, L.; Lodish, H.F.; Bartel, D.P. MicroRNAs modulate hematopoietic lineage differentiation. Science 2004, 303, 83-86. [CrossRef] [PubMed]
13. Wilfred, B.R.; Wang, W.X.; Nelson, P.T. Energizing miRNA research: A review of the role of miRNAs in lipid metabolism, with a prediction that miR-103/107 regulates human metabolic pathways. Mol. Genet. Metab. 2007, 91, 209-217. [CrossRef] [PubMed]
14. Poy, M.N.; Eliasson, L.; Krutzfeldt, J.; Kuwajima, S.; Ma, X.; Macdonald, P.E.; Pfeffer, S.; Tuschl, T.; Rajewsky, N.; Rorsman, P. et al. A pancreatic islet-specific microRNA regulates insulin secretion. Nature 2004, 432, 226-230 [CrossRef] [PubMed]
15. Ikeda, S.; Kong, S.W.; Lu, J.; Bisping, E.; Zhang, H.; Allen, P.D.; Golub, T.R.; Pieske, B.; Pu, W.T. Altered microRNA expression in human heart disease. Physiol. Genomics 2007, 31, 367-373. [CrossRef] [PubMed]
16. Kasinski, A.L.; Slack, F.J. Epigenetics and genetics. microRNAs en route to the clinic: Progress in validating and targeting microRNAs for cancer therapy. Nat. Rev. Cancer 2011, 11, 849-864. [CrossRef] [PubMed]
17. Hebert, S.S.; De Strooper, B. Alterations of the microRNA network cause neurodegenerative disease. Trends Neurosci. 2009, 32, 199-206. [CrossRef] [PubMed]
18. Yanaihara, N.; Caplen, N.; Bowman, E.; Seike, M.; Kumamoto, K.; Yi, M.; Stephens, R.M.; Okamoto, A.; Yokota, J.; Tanaka, T. et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 2006, 9, 189-198. [CrossRef] [PubMed]
19. Schoof, C.R.; Botelho, E.L.; Izzotti, A.; Vasques Ldos, R. MicroRNAs in cancer treatment and prognosis. Am. J. Cancer Res. 2012, 2, 414-433. [PubMed]
20. Jeffrey, S.S. Cancer biomarker profiling with microRNAs. Nat. Biotechnol. 2008, 26, 400-401. [CrossRef] [PubMed]
21. Gregory, R.I.; Chendrimada, T.P.; Shiekhattar, R. MicroRNA biogenesis: Isolation and characterization of the microprocessor complex. Methods Mol. Biol. 2006, 342, 33-47. [PubMed]
22. Morishita, A.; Masaki, T. MiRNA in hepatocellular carcinoma. Hepatol. Res. 2015, 45, 128-141. [CrossRef] [PubMed]
23. Gregory, R.I.; Chendrimada, T.P.; Cooch, N.; Shiekhattar, R. Human RISC couples microRNA biogenesis and posttranscriptional gene silencing. Cell 2005, 123, 631-640. [CrossRef] [PubMed]
24. Kim, Y.; Kim, V.N. MicroRNA factory: RISC assembly from precursor microRNAs. Mol. Cell 2012, 46, 384-386. [CrossRef] [PubMed]
25. Geerts, A. History, heterogeneity, developmental biology, and functions of quiescent hepatic stellate cells. Semin. Liver Dis. 2001, 21, 311-335. [CrossRef] [PubMed]
26. Yin, C.; Evason, K.J.; Asahina, K.; Stainier, D.Y. Hepatic stellate cells in liver development, regeneration, and cancer. J. Clin. Investig. 2013, 123, 1902-1910. [CrossRef] [PubMed]
27. Krizhanovsky, V.; Yon, M.; Dickins, R.A.; Hearn, S.; Simon, J.; Miething, C.; Yee, H.; Zender, L.; Lowe, S.W. Senescence of activated stellate cells limits liver fibrosis. Cell 2008, 134, 657-667. [CrossRef] [PubMed]
28. Kisseleva, T.; Brenner, D.A. Hepatic stellate cells and the reversal of fibrosis. J. Gastroenterol. Hepatol. 2006, 21 (Suppl. 3), S84-S87. [CrossRef] [PubMed]
29. Senoo, H. Structure and function of hepatic stellate cells. Med. Electron. Microsc. 2004, 37, 3-15. [CrossRef] [PubMed]
30. Li, J.T.; Liao, Z.X.; Ping, J.; Xu, D.; Wang, H. Molecular mechanism of hepatic stellate cell activation and antifibrotic therapeutic strategies. J. Gastroenterol. 2008, 43, 419-428. [CrossRef] [PubMed]
31. Sicklick, J.K.; Choi, S.S.; Bustamante, M.; McCall, S.J.; Pérez, E.H.; Huang, J.; Li, Y.X.; Rojkind, M.; Diehl, A.M. Evidence for epithelial-mesenchymal transitions in adult liver cells. Am. J. Physiol. Gastrointest. Liver Physiol. 2006, 291, G575-G583. [CrossRef] [PubMed]
32. Miyata, E.; Masuya, M.; Yoshida, S.; Nakamura, S.; Kato, K.; Sugimoto, Y.; Shibasaki, T.; Yamamura, K.; Ohishi, K.; Nishii, K. et al. Hematopoietic origin of hepatic stellate cells in the adult liver. Blood 2008, 111, 2427-2435. [CrossRef] [PubMed]
33. Baba, S.; Fujii, H.; Hirose, T.; Yasuchika, K.; Azuma, H.; Hoppo, T.; Naito, M.; Machimoto, T.; Ikai, I. Commitment of bone marrow cells to hepatic stellate cells in mouse. J. Hepatol. 2004, 40, 255-260. [CrossRef] [PubMed]
34. Knittel, T.; Kobold, D.; Saile, B.; Grundmann, A.; Neubauer, K.; Piscaglia, F.; Ramadori, G. Rat liver myofibroblasts and hepatic stellate cells: Different cell populations of the fibroblast lineage with fibrogenic potential. Gastroenterology 1999, 117, 1205-1221. [CrossRef]
35. Canbay, A.; Friedman, S.; Gores, G.J. Apoptosis: The nexus of liver injury and fibrosis. Hepatology 2004, 39, 273-278. [CrossRef] [PubMed]
36. Iredale, J.P.; Benyon, R.C.; Pickering, J.; McCullen, M.; Northrop, M.; Pawley, S.; Hovell, C.; Arthur, M.J. Mechanisms of spontaneous resolution of rat liver fibrosis. Hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors. J. Clin. Investig. 1998, 102, 538-549. [CrossRef] [PubMed]
37. Issa, R.; Williams, E.; Trim, N.; Kendall, T.; Arthur, M.J.; Reichen, J.; Benyon, R.C.; Iredale, J.P. Apoptosis of hepatic stellate cells: Involvement in resolution of biliary fibrosis and regulation by soluble growth factors. Gut 2001, 48, 548-557. [CrossRef] [PubMed]
38. Wallace, M.C.; Friedman, S.L. Hepatic fibrosis and the microenvironment: Fertile soil for hepatocellular carcinoma development. Gene Expr. 2014, 16, 77-84. [CrossRef] [PubMed]
39. Du, J.; Niu, X.; Wang, Y.; Kong, L.; Wang, R.; Zhang, Y.; Zhao, S.; Nan, Y. MiR-146a-5p suppresses activation and proliferation of hepatic stellate cells in nonalcoholic fibrosing steatohepatitis through directly targeting Wnt1 and Wnt5a. Sci. Rep. 2015, 5, 16163. [CrossRef] [PubMed]
40. Leti, F.; Malenica, I.; Doshi, M.; Courtright, A.; Van Keuren-Jensen, K.; Legendre, C.; Still, C.D.; Gerhard, G.S.; DiStefano, J.K. High-throughput sequencing reveals altered expression of hepatic microRNAs in nonalcoholic fatty liver disease-related fibrosis. Transl. Res. 2015, 166, 304-314. [CrossRef] [PubMed]
41. Guo, C.J.; Pan, Q.; Cheng, T.; Jiang, B.; Chen, G.Y.; Li, D.G. Changes in microRNAs associated with hepatic stellate cell activation status identify signaling pathways. FEBS J. 2009, 276, 5163-5176. [CrossRef] [PubMed]
42. Guo, C.J.; Pan, Q.; Li, D.G.; Sun, H.; Liu, B.W. MiR-15b and miR-16 are implicated in activation of the rat hepatic stellate cell: An essential role for apoptosis. J. Hepatol. 2009, 50, 766-778. [CrossRef] [PubMed]
43. Lakner, A.M.; Steuerwald, N.M.; Walling, T.L.; Ghosh, S.; Li, T.; McKillop, I.H.; Russo, M.W.; Bonkovsky, H.L.; Schrum, L.W. Inhibitory effects of microRNA 19b in hepatic stellate cell-mediated fibrogenesis. Hepatology 2012, 56, 300-310. [CrossRef] [PubMed]
44. Maubach, G.; Lim, M.C.; Chen, J.; Yang, H.; Zhuo, L. miRNA studies in in vitro and in vivo activated hepatic stellate cells. World J. Gastroenterol. 2011, 17, 2748-2773. [PubMed]
45. Murakami, Y.; Toyoda, H.; Tanaka, M.; Kuroda, M.; Harada, Y.; Matsuda, F.; Tajima, A.; Kosaka, N.; Ochiya, T.; Shimotohno, K. The progression of liver fibrosis is related with overexpression of the miR-199 and 200 families. PLoS ONE 2011, 6, e16081. [CrossRef] [PubMed]
46. Roderburg, C.; Urban, G.W.; Bettermann, K.; Vucur, M.; Zimmermann, H.; Schmidt, S.; Janssen, J.; Koppe, C.; Knolle, P.; Castoldi, M. et al. Micro-RNA profiling reveals a role for miR-29 in human and murine liver fibrosis. Hepatology 2011, 53, 209-218. [CrossRef] [PubMed]
47. Cheung, O.; Puri, P.; Eicken, C.; Contos, M.J.; Mirshahi, F.; Maher, J.W.; Kellum, J.M.; Min, H.; Luketic, V.A.; Sanyal, A.J. Nonalcoholic steatohepatitis is associated with altered hepatic microRNA expression. Hepatology 2008, 48, 1810-1820. [CrossRef] [PubMed]
48. De Minicis, S.; Seki, E.; Uchinami, H.; Kluwe, J.; Zhang, Y.; Brenner, D.A.; Schwabe, R.F. Gene expression profiles during hepatic stellate cell activation in culture and in vivo. Gastroenterology 2007, 132, 1937-1946. [CrossRef] [PubMed]
49. Qi, F.; Hu, J.F.; Liu, B.H.; Wu, C.Q.; Yu, H.Y.; Yao, D.K.; Zhu, L. MiR-9a-5p regulates proliferation and migration of hepatic stellate cells under pressure through inhibition of Sirt1. World J. Gastroenterol. 2015, 21, 9900-9915. [CrossRef] [PubMed]
50. Yu, F.; Guo, Y.; Chen, B.; Dong, P.; Zheng, J. MicroRNA-17-5p activates hepatic stellate cells through targeting of Smad7. Lab Investig. 2015, 95, 781-789. [PubMed]
51. Wei, J.; Feng, L.; Li, Z.; Xu, G.; Fan, X. MicroRNA-21 activates hepatic stellate cells via PTEN/Akt signaling. Biomed. Pharmacother. 2013, 67, 387-392. [CrossRef] [PubMed]
52. Zhang, Z.; Zha, Y.; Hu, W.; Huang, Z.; Gao, Z.; Zang, Y.; Chen, J.; Dong, L.; Zhang, J. The autoregulatory feedback loop of microRNA-21/programmed cell death protein 4/activation protein-1 (miR-21/PDCD4/AP-1) as a driving force for hepatic fibrosis development. J. Biol. Chem. 2013, 288, 37082-37093. [CrossRef] [PubMed]
53. Zhao, J.; Tang, N.; Wu, K.; Dai, W.; Ye, C.; Shi, J.; Zhang, J.; Ning, B.; Zeng, X.; Lin, Y. MiR-21 simultaneously regulates ERK1 signaling in HSC activation and hepatocyte EMT in hepatic fibrosis. PLoS ONE 2014, 9, e108005. [CrossRef] [PubMed]
54. Hu, J.; Chen, C.; Liu, Q.; Liu, B.; Song, C.; Zhu, S.; Wu, C.; Liu, S.; Yu, H.; Yao, D. et al. The role of miR-31/FIH1 pathway in TGFbeta-induced liver fibrosis. Clin. Sci. (Lond.) 2015, 129, 305-317. [CrossRef] [PubMed]
55. Li, Z.J.; Ou-Yang, P.H.; Han, X.P. Profibrotic effect of miR-33a with Akt activation in hepatic stellate cells. Cell. Signal. 2014, 26, 141-148. [CrossRef] [PubMed]
56. Tomita, K.; Teratani, T.; Suzuki, T.; Shimizu, M.; Sato, H.; Narimatsu, K.; Okada, Y.; Kurihara, C.; Irie, R.; Yokoyama, H. et al. Free cholesterol accumulation in hepatic stellate cells: Mechanism of liver fibrosis aggravation in nonalcoholic steatohepatitis in mice. Hepatology 2014, 59, 154-169. [CrossRef] [PubMed]
57. Li, X.; Chen, Y.; Wu, S.; He, J.; Lou, L.; Ye, W.; Wang, J. MicroRNA-34a and microRNA-34c promote the activation of human hepatic stellate cells by targeting peroxisome proliferator-activated receptor gamma. Mol. Med. Rep. 2015, 11, 1017-1024. [PubMed]
58. Yan, G.; Li, B.; Xin, X.; Xu, M.; Ji, G.; Yu, H. MicroRNA-34a Promotes Hepatic Stellate Cell Activation via Targeting ACSL1. Med. Sci. Monit. 2015, 21, 3008-3015. [CrossRef] [PubMed]
59. Feng, X.; Tan, W.; Cheng, S.; Wang, H.; Ye, S.; Yu, C.; He, Y.; Zeng, J.; Cen, J.; Hu, J. Upregulation of microRNA-126 in hepatic stellate cells may affect pathogenesis of liver fibrosis through the NF-kappaB pathway. DNA Cell Biol. 2015, 34, 470-480. [CrossRef] [PubMed]
60. Lu, L.; Wang, J.; Lu, H.; Zhang, G.; Liu, Y.; Zhang, Y.; Shang, H.; Ji, H.; Chen, X.; Duan, Y. et al. MicroRNA-130a and-130b enhance activation of hepatic stellate cells by suppressing PPARgamma expression: A rat fibrosis model study. Biochem. Biophys. Res. Commun. 2015, 465, 387-393. [CrossRef] [PubMed]
61. Morita, K.; Taketomi, A.; Shirabe, K.; Umeda, K.; Kayashima, H.; Ninomiya, M.; Uchiyama, H.; Soejima, Y.; Maehara, Y. Clinical significance and potential of hepatic microRNA-122 expression in hepatitis C. Liver Int. 2011, 31, 474-484. [CrossRef] [PubMed]
62. Chen, L.; Chen, R.; Kemper, S.; Charrier, A.; Brigstock, D.R. Suppression of fibrogenic signaling in hepatic stellate cells by Twist1-dependent microRNA-214 expression: Role of exosomes in horizontal transfer of Twist1. Am. J. Physiol. Gastrointest. Liver Physiol. 2015, 309, G491-G499. [CrossRef] [PubMed]
63. Iizuka, M.; Ogawa, T.; Enomoto, M.; Motoyama, H.; Yoshizato, K.; Ikeda, K.; Kawada, N. Induction of microRNA-214-5p in human and rodent liver fibrosis. Fibrogenesis Tissue Repair 2012, 5, 12. [CrossRef] [PubMed]
64. Ogawa, T.; Enomoto, M.; Fujii, H.; Sekiya, Y.; Yoshizato, K.; Ikeda, K.; Kawada, N. MicroRNA-221/222 upregulation indicates the activation of stellate cells and the progression of liver fibrosis. Gut 2012, 61, 1600-1609. [CrossRef] [PubMed]
65. Guo, C.J.; Pan, Q.; Jiang, B.; Chen, G.Y.; Li, D.G. Effects of upregulated expression of microRNA-16 on biological properties of culture-activated hepatic stellate cells. Apoptosis 2009, 14, 1331-1340. [CrossRef] [PubMed]
66. Ge, S.; Xie, J.; Liu, F.; He, J. MicroRNA-19b reduces hepatic stellate cell proliferation by targeting GRB2 in hepatic fibrosis models in vivo and in vitro as part of the inhibitory effect of estradiol. J. Cell. Biochem. 2015, 116, 2455-2464. [CrossRef] [PubMed]
67. Bandyopadhyay, S.; Friedman, R.C.; Marquez, R.T.; Keck, K.; Kong, B.; Icardi, M.S.; Brown, K.E.; Burge, C.B.; Schmidt, W.N.; Wang, Y. et al. Hepatitis C virus infection and hepatic stellate cell activation downregulate miR-29: MiR-29 overexpression reduces hepatitis C viral abundance in culture. J. Infect. Dis. 2011, 203, 1753-1762. [CrossRef] [PubMed]
68. Kwiecinski, M.; Noetel, A.; Elfimova, N.; Trebicka, J.; Schievenbusch, S.; Strack, I.; Molnar, L.; von Brandenstein, M.; Töx, U.; Nischt, R. et al. Hepatocyte growth factor (HGF) inhibits collagen I and IV synthesis in hepatic stellate cells by miRNA-29 induction. PLoS ONE 2011, 6, e24568. [CrossRef] [PubMed]
69. Kwiecinski, M.; Elfimova, N.; Noetel, A.; Töx, U.; Steffen, H.M.; Hacker, U.; Nischt, R.; Dienes, H.P.; Odenthal, M. Expression of platelet-derived growth factor-C and insulin-like growth factor I in hepatic stellate cells is inhibited by miR-29. Lab Investig. 2012, 92, 978-987. [CrossRef] [PubMed]
70. Ogawa, T.; Iizuka, M.; Sekiya, Y.; Yoshizato, K.; Ikeda, K.; Kawada, N. Suppression of type I collagen production by microRNA-29b in cultured human stellate cells. Biochem. Biophys. Res. Commun. 2010, 391, 316-321. [CrossRef] [PubMed]
71. Huang, Y.H.; Tiao, M.M.; Huang, L.T.; Chuang, J.H.; Kuo, K.C.; Yang, Y.L.; Wang, F.S. Activation of miR-29a in activated hepatic stellate cells modulates its profibrogenic phenotype through inhibition of histone deacetylases 4. PLoS ONE 2015, 10, e0136453. [CrossRef] [PubMed]
72. Tiao, M.M.; Wang, F.S.; Huang, L.T.; Chuang, J.H.; Kuo, H.C.; Yang, Y.L.; Huang, Y.H. MicroRNA-29a protects against acute liver injury in a mouse model of obstructive jaundice via inhibition of the extrinsic apoptosis pathway. Apoptosis 2014, 19, 30-41. [CrossRef] [PubMed]
73. Zhang, Y.; Ghazwani, M.; Li, J.; Sun, M.; Stolz, D.B.; He, F.; Fan, J.; Xie, W.; Li, S. MiR-29b inhibits collagen maturation in hepatic stellate cells through down-regulating the expression of HSP47 and lysyl oxidase. Biochem. Biophys. Res. Commun. 2014, 446, 940-944. [CrossRef] [PubMed]
74. Zheng, J.; Wu, C.; Lin, Z.; Guo, Y.; Shi, L.; Dong, P.; Lu, Z.; Gao, S.; Liao, Y.; Chen, B. et al. Curcumin up-regulates phosphatase and tensin homologue deleted on chromosome 10 through microRNA-mediated control of DNA methylation—A novel mechanism suppressing liver fibrosis. FEBS J. 2014, 281, 88-103. [CrossRef] [PubMed]
75. Tu, X.; Zheng, X.; Li, H.; Cao, Z.; Chang, H.; Luan, S.; Zhu, J.; Chen, J.; Zang, Y.; Zhang, J. MicroRNA-30 protect against CCl4-induced liver fibrosis by attenuating TGF-beta signaling in hepatic stellate cells. Toxicol. Sci. 2015, 146, 157-169. [CrossRef] [PubMed]
76. Tu, X.; Zhang, H.; Zhang, J.; Zhao, S.; Zheng, X.; Zhang, Z.; Zhu, J.; Chen, J.; Dong, L.; Zang, Y. MicroRNA-101 suppresses liver fibrosis by targeting the TGF-beta signalling pathway. J. Pathol. 2014, 234, 46-59. [CrossRef] [PubMed]
77. Li, J.; Ghazwani, M.; Zhang, Y.; Lu, J.; Fan, J.; Gandhi, C.R.; Li, S. MiR-122 regulates collagen production via targeting hepatic stellate cells and suppressing P4HA1 expression. J. Hepatol. 2013, 58, 522-528. [CrossRef] [PubMed]
78. Zeng, C.; Wang, Y.L.; Xie, C.; Sang, Y.; Li, T.J.; Zhang, M.; Wang, R.; Zhang, Q.; Zheng, L.; Zhuang, S.M. Identification of a novel TGF-beta-miR-122-fibronectin 1/serum response factor signaling cascade and its implication in hepatic fibrogenesis. Oncotarget 2015, 6, 12224-12233. [CrossRef] [PubMed]
79. Guo, C.J.; Pan, Q.; Xiong, H.; Qiao, Y.Q.; Bian, Z.L.; Zhong, W.; Sheng, L.; Li, H.; Shen, L.; Hua, J. et al. Dynamic expression of miR-126* and its effects on proliferation and contraction of hepatic stellate cells. FEBS Lett. 2013, 587, 3792-3801. [CrossRef] [PubMed]
80. Roderburg, C.; Luedde, M.; Vargas, C.D.; Vucur, M.; Mollnow, T.; Zimmermann, H.W.; Koch, A.; Hellerbrand, C.; Weiskirchen, R.; Frey, N.; et al. MiR-133a mediates TGF-beta-dependent derepression of collagen synthesis in hepatic stellate cells during liver fibrosis. J. Hepatol. 2013, 58, 736-742. [CrossRef] [PubMed]
81. Liu, Z.; Yi, J.; Ye, R.; Liu, J.; Duan, Q.; Xiao, J.; Liu, F. miR-144 regulates transforming growth factor-beta1 iduced hepatic stellate cell activation in human fibrotic liver. Int. J. Clin. Exp. Pathol. 2015, 8, 3994-4000.
82. He, Y.; Huang, C.; Sun, X.; Long, X.R.; Lv, X.W.; Li, J. MicroRNA-146a modulates TGF-beta1-induced hepatic stellate cell proliferation by targeting SMAD4. Cell. Signal. 2012, 24, 1923-1930. [CrossRef] [PubMed]
83. Venugopal, S.K.; Jiang, J.; Kim, T.H.; Li, Y.; Wang, S.S.; Torok, N.J.; Wu, J.; Zern, M.A. Liver fibrosis causes downregulation of miRNA-150 and miRNA-194 in hepatic stellate cells, and their overexpression causes decreased stellate cell activation. Am. J. Physiol. Gastrointest. Liver Physiol. 2010, 298, G101-G106. [CrossRef] [PubMed]
84. Zheng, J.; Lin, Z.; Dong, P.; Lu, Z.; Gao, S.; Chen, X.; Wu, C.; Yu, F. Activation of hepatic stellate cells is suppressed by microRNA-150. Int. J. Mol. Med. 2013, 32, 17-24. [PubMed]
85. Dai, W.; Zhao, J.; Tang, N.; Zeng, X.; Wu, K.; Ye, C.; Shi, J.; Lu, C.; Ning, B.; Zhang, J. et al. MicroRNA-155 attenuates activation of hepatic stellate cell by simultaneously preventing EMT process and ERK1 signalling pathway. Liver Int. 2015, 35, 1234-1243. [CrossRef] [PubMed]
86. Sekiya, Y.; Ogawa, T.; Iizuka, M.; Yoshizato, K.; Ikeda, K.; Kawada, N. Down-regulation of cyclin E1 expression by microRNA-195 accounts for interferon-beta-induced inhibition of hepatic stellate cell proliferation. J. Cell. Physiol. 2011, 226, 2535-2542. [CrossRef] [PubMed]
87. Yang, J.J.; Tao, H.; Hu, W.; Liu, L.P.; Shi, K.H.; Deng, Z.Y.; Li, J. MicroRNA-200a controls Nrf2 activation by target Keap1 in hepatic stellate cell proliferation and fibrosis. Cell. Signal. 2014, 26, 2381-2389. [CrossRef] [PubMed]
88. Sun, X.; He, Y.; Ma, T.T.; Huang, C.; Zhang, L.; Li, J. Participation of miR-200a in TGF-beta1-mediated hepatic stellate cell activation. Mol. Cell. Biochem. 2014, 388, 11-23. [CrossRef] [PubMed]
89. Chen, L.; Charrier, A.; Zhou, Y.; Chen, R.; Yu, B.; Agarwal, K.; Tsukamoto, H.; Lee, L.J.; Paulaitis, M.E.; Brigstock, D.R. Epigenetic regulation of connective tissue growth factor by microRNA-214 delivery in exosomes from mouse or human hepatic stellate cells. Hepatology 2014, 59, 1118-1129. [CrossRef] [PubMed]
90. Chen, C.; Wu, C.Q.; Zhang, Z.Q.; Yao, D.K.; Zhu, L. Loss of expression of miR-335 is implicated in hepatic stellate cell migration and activation. Exp. Cell Res. 2011, 317, 1714-1725. [CrossRef] [PubMed]
91. Lu, C.H.; Hou, Q.R.; Deng, L.F.; Fei, C.; Xu, W.P.; Zhang, Q.; Wu, K.M.; Ning, B.F.; Xie, W.F.; Zhang, X. MicroRNA-370 Attenuates Hepatic Fibrogenesis by Targeting Smoothened. Dig. Dis. Sci. 2015, 60, 2038-2048. [CrossRef] [PubMed]
92. Zhu, D.; He, X.; Duan, Y.; Chen, J.; Wang, J.; Sun, X.; Qian, H.; Feng, J.; Sun, W.; Xu, F. et al. Expression of microRNA-454 in TGF-beta1-stimulated hepatic stellate cells and in mouse livers infected with Schistosoma japonicum. Parasit. Vectors 2014, 7, 148. [CrossRef] [PubMed]
93. Li, F.; Ma, N.; Zhao, R.; Wu, G.; Zhang, Y.; Qiao, Y.; Han, D.; Xu, Y.; Xiang, Y.; Yan, B. et al. Overexpression of miR-483-5p/3p cooperate to inhibit mouse liver fibrosis by suppressing the TGF-beta stimulated HSCs in transgenic mice. J. Cell. Mol. Med. 2014, 18, 966-974. [CrossRef] [PubMed]
94. Wang, J.; Chu, E.S.; Chen, H.Y.; Man, K.; Go, M.Y.; Huang, X.R.; Lan, H.Y.; Sung, J.J.; Yu, J. MicroRNA-29b prevents liver fibrosis by attenuating hepatic stellate cell activation and inducing apoptosis through targeting PI3K/AKT pathway. Oncotarget 2015, 6, 7325-7338. [CrossRef] [PubMed]
95. Mannaerts, I.; Eysackers, N.; Onyema, O.O.; Van Beneden, K.; Valente, S.; Mai, A.; Odenthal, M.; van Grunsven, L.A. Class II HDAC inhibition hampers hepatic stellate cell activation by induction of microRNA-29. PLoS ONE 2013, 8, e55786. [CrossRef] [PubMed]
96. Sekiya, Y.; Ogawa, T.; Yoshizato, K.; Ikeda, K.; Kawada, N. Suppression of hepatic stellate cell activation by microRNA-29b. Biochem. Biophys. Res. Commun. 2011, 412, 74-79. [CrossRef] [PubMed]
97. Zheng, J.; Wu, C.; Xu, Z.; Xia, P.; Dong, P.; Chen, B.; Yu, F. Hepatic stellate cell is activated by microRNA-181b via PTEN/Akt pathway. Mol. Cell. Biochem. 2015, 398, 1-9. [CrossRef] [PubMed]
98. Chang, X.M.; Chang, Y.; Jia, A. Effects of interferon-alpha on expression of hepatic stellate cell and transforming growth factor-beta1 and alpha-smooth muscle actin in rats with hepatic fibrosis. World J. Gastroenterol. 2005, 11, 2634-2636. [CrossRef] [PubMed]
99. Ogawa, T.; Kawada, N.; Ikeda, K. Effect of natural interferon alpha on proliferation and apoptosis of hepatic stellate cells. Hepatol. Int. 2009, 3, 497-503. [CrossRef] [PubMed]
100. Tanabe, J.; Izawa, A.; Takemi, N.; Miyauchi, Y.; Torii, Y.; Tsuchiyama, H.; Suzuki, T.; Sone, S.; Ando, K. Interferon-beta reduces the mouse liver fibrosis induced by repeated administration of concanavalin A via the direct and indirect effects. Immunology 2007, 122, 562-570. [CrossRef] [PubMed]
101. Yang, C.; Zeisberg, M.; Mosterman, B.; Sudhakar, A.; Yerramalla, U.; Holthaus, K.; Xu, L.; Eng, F.; Afdhal, N.; Kalluri, R. Liver fibrosis: Insights into migration of hepatic stellate cells in response to extracellular matrix and growth factors. Gastroenterology 2003, 124, 147-159. [CrossRef] [PubMed]
102. Yu, F.; Lin, Z.; Zheng, J.; Gao, S.; Lu, Z.; Dong, P. Suppression of collagen synthesis by Dicer gene silencing in hepatic stellate cells. Mol. Med. Rep. 2014, 9, 707-714. [PubMed]
103. Yu, F.; Lu, Z.; Chen, B.; Wu, X.; Dong, P.; Zheng, J. Salvianolic acid B-induced microRNA-152 inhibits liver fibrosis by attenuating DNMT1-mediated Patched1 methylation. J. Cell. Mol. Med. 2015, 19, 2617-2632. [CrossRef] [PubMed]
104. Knabel, M.K.; Ramachandran, K.; Karhadkar, S.; Hwang, H.W.; Creamer, T.J.; Chivukula, R.R.; Sheikh, F.; Clark, K.R.; Torbenson, M.; Montgomery, R.A. et al. Systemic Delivery of scAAV8-Encoded MiR-29a Ameliorates Hepatic Fibrosis in Carbon Tetrachloride-Treated Mice. PLoS ONE 2015, 10, e0124411.
105. Li, J.; Zhang, Y.; Kuruba, R.; Gao, X.; Gandhi, C.R.; Xie, W.; Li, S. Roles of microRNA-29a in the antifibrotic effect of farnesoid X receptor in hepatic stellate cells. Mol. Pharmacol. 2011, 80, 191-200. [CrossRef] [PubMed]
106. Chang, Y.; Jiang, H.J.; Sun, X.M.; Cai, X.K.; He, X.X.; Li, P.Y.; Tang, W.X.; Song, Y.H.; Lin, J.S. Hepatic stellate cell-specific gene silencing induced by an artificial microRNA for antifibrosis in vitro. Dig. Dis. Sci. 2010, 55, 642-653. [CrossRef] [PubMed]
107. Zhang, Z.; Gao, Z.; Hu, W.; Yin, S.; Wang, C.; Zang, Y.; Chen, J.; Zhang, J.; Dong, L. 3,31-Diindolylmethane ameliorates experimental hepatic fibrosis via inhibiting miR-21 expression. Br. J. Pharmacol. 2013, 170, 649-660. [CrossRef] [PubMed]
108. Shu, J.C.; He, Y.J.; Lv, X.; Ye, G.R.; Wang, L.X. Curcumin prevents liver fibrosis by inducing apoptosis and suppressing activation of hepatic stellate cells. J. Nat. Med. 2009, 63, 415-420. [CrossRef] [PubMed]
109. Janssen, H.L.; Reesink, H.W.; Lawitz, E.J.; Zeuzem, S.; Rodriguez-Torres, M.; Patel, K.; van der Meer, A.J.; Patick, A.K.; Chen, A.; Zhou, Y. et al. Treatment of HCV infection by targeting microRNA. Newe Engl. J. Med. 2013, 368, 1685-1694. [CrossRef] [PubMed]
110. Van der Ree, M.H.; van der Meer, A.J.; de Bruijne, J.; Maan, R.; van Vliet, A.; Welzel, T.M.; Zeuzem, S.; Lawitz, E.J.; Rodriguez-Torres, M.; Kupcova, V. et al. Long-term safety and efficacy of microRNA-targeted therapy in chronic hepatitis C patients. Antiviral Res. 2014, 111, 53-59. [CrossRef] [PubMed]
111. Chen, X.; Ba, Y.; Ma, L.; Cai, X.; Yin, Y.; Wang, K.; Guo, J.; Zhang, Y.; Chen, J.; Guo, X. et al. Characterization of microRNAs in serum: A novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 2008, 18, 997-1006. [CrossRef] [PubMed]
112. Mitchell, P.S.; Parkin, R.K.; Kroh, E.M.; Fritz, B.R.; Wyman, S.K.; Pogosova-Agadjanyan, E.L.; Peterson, A.; Noteboom, J.; O’Briant, K.C.; Allen, A. et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl. Acad. Sci. USA 2008, 105, 10513-10518. [CrossRef] [PubMed]
113. Creemers, E.E.; Tijsen, A.J.; Pinto, Y.M. Circulating microRNAs: Novel biomarkers and extracellular communicators in cardiovascular disease? Circ. Res. 2012, 110, 483-495. [CrossRef] [PubMed]
114. Cortez, M.A.; Bueso-Ramos, C.; Ferdin, J.; Lopez-Berestein, G.; Sood, A.K.; Calin, G.A. MicroRNAs in body fluids—the mix of hormones and biomarkers. Nat. Rev. Clin. Oncol. 2011, 8, 467-477. [CrossRef] [PubMed]
115. Hu, J.; Xu, Y.; Hao, J.; Wang, S.; Li, C.; Meng, S. MiR-122 in hepatic function and liver diseases. Protein Cell 2012, 3, 364-371. [CrossRef] [PubMed]
116. Bihrer, V.; Friedrich-Rust, M.; Kronenberger, B.; Forestier, N.; Haupenthal, J.; Shi, Y.; Peveling-Oberhag, J.; Radeke, H.H.; Sarrazin, C.; Herrmann, E. et al. Serum miR-122 as a biomarker of necroinflammation in patients with chronic hepatitis C virus infection. Am. J. Gastroenterol. 2011, 106, 1663-1669. [CrossRef] [PubMed]
117. Cermelli, S.; Ruggieri, A.; Marrero, J.A.; Ioannou, G.N.; Beretta, L. Circulating microRNAs in patients with chronic hepatitis C and non-alcoholic fatty liver disease. PLoS ONE 2011, 6, e23937. [CrossRef] [PubMed]
118. Zhang, Y.; Jia, Y.; Zheng, R.; Guo, Y.; Wang, Y.; Guo, H.; Fei, M.; Sun, S. Plasma microRNA-122 as a biomarker for viral-, alcohol-, and chemical-related hepatic diseases. Clin. Chem. 2010, 56, 1830-1838. [CrossRef] [PubMed]
119. Qi, J.; Wang, J.; Katayama, H.; Sen, S.; Liu, S.M. Circulating microRNAs (cmiRNAs) as novel potential biomarkers for hepatocellular carcinoma. Neoplasma 2013, 60, 135-142. [CrossRef] [PubMed]
120. Trebicka, J.; Anadol, E.; Elfimova, N.; Strack, I.; Roggendorf, M.; Viazov, S.; Wedemeyer, I.; Drebber, U.; Rockstroh, J.; Sauerbruch, T. et al. Hepatic and serum levels of miR-122 after chronic HCV-induced fibrosis. J. Hepatol. 2013, 58, 234-239. [CrossRef] [PubMed]
121. Wang, B.; Li, W.; Guo, K.; Xiao, Y.; Wang, Y.; Fan, J. miR-181b promotes hepatic stellate cells proliferation by targeting p27 and is elevated in the serum of cirrhosis patients. Biochem. Biophys. Res. Commun. 2012, 421, 4-8. [CrossRef] [PubMed]
122. Roderburg, C.; Luedde, T. Circulating microRNAs as markers of liver inflammation, fibrosis and cancer. J. Hepatol. 2014, 61, 1434-1437. [CrossRef] [PubMed]
123. Huang, C.F.; Sun, C.C.; Zhao, F.; Zhang, Y.D.; Li, D.J. MiR-33a levels in hepatic and serum after chronic HBV-induced fibrosis. J. Gastroenterol. 2015, 50, 480-490. [CrossRef] [PubMed]
124. Bala, S.; Petrasek, J.; Mundkur, S.; Catalano, D.; Levin, I.; Ward, J.; Alao, H.; Kodys, K.; Szabo, G. Circulating microRNAs in exosomes indicate hepatocyte injury and inflammation in alcoholic, drug-induced, and inflammatory liver diseases. Hepatology 2012, 56, 1946-1957. [CrossRef] [PubMed]
125. Jansen, C.; Eischeid, H.; Goertzen, J.; Schierwagen, R.; Anadol, E.; Strassburg, C.P.; Sauerbruch, T.; Odenthal, M.; Trebicka, J. The role of miRNA-34a as a prognostic biomarker for cirrhotic patients with portal hypertension receiving TIPS. PLoS ONE 2014, 9, e103779. [CrossRef] [PubMed]
126. Jansen, C.; Reiberger, T.; Huang, J.; Eischeid, H.; Schierwagen, R.; Mandorfer, M.; Anadol, E.; Schwabl, P.; Schwarze-Zander, C.; Warnecke-Eberz, U. et al. Circulating miRNA-122 levels are associated with hepatic necroinflammation and portal hypertension in HIV/HCV coinfection. PLoS ONE 2015, 10, e0116768. [CrossRef] [PubMed]
127. Anadol, E.; Schierwagen, R.; Elfimova, N.; Tack, K.; Schwarze-Zander, C.; Eischeid, H.; Noetel, A.; Boesecke, C.; Jansen, C.; Dold, L. et al. Circulating microRNAs as a marker for liver injury in human immunodeficiency virus patients. Hepatology 2015, 61, 46-55. [CrossRef] [PubMed]
128. Centers for Disease Control and Prevention. Chronic Liver Disease and Cirrhosis. Available online: http://www.cdc.gov/nchs/fastats/liver-disease.htm (accessed on 17 June 2015).
129. ClinicalTrials.Gov. Available online: https://clinicaltrials.gov/ct2/results?term=microrna&Search=Search (accessed on 11 June 2015).